Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer Institute, shared a post by The ASCO Post on X, adding:
“Thanks to The ASCO Post for highlighting our work in this important clinical gray zone. While awaiting prospective data, our findings support prioritizing CT-ICI over ICI alone in PD-L1–high NSCLC.
Kudos to Alessandro Di Federico an amazing scientist and the first author of this study.”
Quoting The ASCO Post’s post:
“A new meta-analysis suggests first-line chemoimmunotherapy may provide greater OS benefit than IO monotherapy in patients with advanced NSCLC with high PD-L1 expression (≥50%).”
You can also read:
Can AI-Supported Navigation Help Close the Lung Nodule Follow-Up Gap?
